



# PLAN REVIEW


## PHARMACY BENEFIT PERFORMANCE

Account: Greater Tompkins County

Date: 01/01/2023 to 12/31/2023

---

# PLAN REVIEW AGENDA





## PLAN SUMMARY

• • •

Review of Plan Sponsor  
Pharmacy Benefit  
Performance



# PLAN COST SUMMARY



| Key Performance Indicators (KPI) | Current Period  | Previous Period | % Change (L/Y) |
|----------------------------------|-----------------|-----------------|----------------|
| Membership                       | 1.1.23-12.31.23 | 1.1.22-12.31.22 |                |
| Average Account Members          | 6,980           | 6,574           | 6.18%          |
| Utilizing Member Count           | 5,915           | 5,289           | 11.84%         |
| Member Paid                      | \$1,112,568     | \$957,390       | 16.21%         |
| Member Share %                   | 4.87%           | 5.30%           | -0.43%         |
| Account Plan Paid PMPM           | \$259.26        | \$216.96        | 19.49%         |
| <b>Claims</b>                    |                 |                 |                |
| Total Rx Count                   | 118,579         | 105,344         | 12.56%         |
| Retail                           | 107,724         | 94,628          | 13.84%         |
| - Retail Maintenance             | 77,518          | 67,723          | 14.46%         |
| Mail Order                       | 9,292           | 9,340           | -0.51%         |
| Specialty                        | 1,563           | 1,376           | 13.59%         |
| Generic Dispensing Rate (GDR)    | 85.44%          | 85.09%          | 0.35%          |

# PLAN COST KPIs



| Key Performance Indicators (KPI)         | Current Period         | Previous Period        | % Change (L/Y) |
|--|------------------------|------------------------|----------------|
| <b>Total Rx Spend</b>                    | <b>1.1.23-12.31.23</b> | <b>1.1.22-12.31.22</b> |                |
| Total Cost                               | \$22,862,694           | \$18,078,150           | 26.47%         |
| Total Copay Assistance                   | \$29,575               | \$26,970               | 9.66%          |
| Total Plan Paid                          | \$21,720,551           | \$17,093,790           | 27.07%         |
| Dispensing Fee                           | \$55,583               | \$49,441               | 12.42%         |
| <b>Plan Paid</b>                         |                        |                        |                |
| Specialty Plan Paid                      | \$11,110,769           | \$8,727,780            | 27.30%         |
| Non-Specialty Plan Paid                  | \$10,609,783           | \$8,366,010            | 26.82%         |
| <b>Channel (Non-Specialty Plan Paid)</b> |                        |                        |                |
| Retail Plan Paid                         | \$8,932,964            | \$6,813,505            | 31.11%         |
| Mail Order Plan Paid                     | \$1,676,819            | \$1,552,505            | 8.01%          |

# PLAN PAID KPIs



| KPI                                    | Current Period  | Previous Period | % Change (L/Y) |
|--|-----------------|-----------------|----------------|
| Drug Type (Plan Paid)                  | 1.1.23-12.31.23 | 1.1.22-12.31.22 |                |
| Generic Plan Paid                      | \$2,735,584     | \$2,398,534     | 14.05%         |
| Brand Plan Paid                        | \$18,984,968    | \$14,695,256    | 29.19%         |
| <b>Average per Rx</b>                  |                 |                 |                |
| Average Total Cost                     | \$192.81        | \$171.61        | 12.35%         |
| Average Plan Paid                      | \$183.17        | \$162.27        | 12.88%         |
| Average Member Paid                    | \$9.38          | \$9.09          | 3.24%          |
| <b>Average Plan Paid per Drug Type</b> |                 |                 |                |
| Brand Average Plan Paid                | \$521.18        | \$436.07        | 19.52%         |
| Generic Average Plan Paid              | \$21.88         | \$21.95         | -0.33%         |
| Specialty Average Plan Paid            | \$7,108.62      | \$6,342.86      | 12.07%         |

# SUMMARY BY TIER



|                            | Rx Count Current | Rx Count Previous | Plan Paid Current | Plan Paid Previous | Total Cost Current | Total Cost Previous |
|----------------------------|------------------|-------------------|-------------------|--------------------|--------------------|---------------------|
| <b>Non-specialty</b>       |                  |                   |                   |                    |                    |                     |
| <b>Tier 1</b>              | 100,914          | 89,439            | \$2,211,797.70    | \$1,993,535.15     | \$2,825,358.97     | \$2,565,546.76      |
| <b>Tier 2</b>              | 10,746           | 11,474            | \$6,618,705.31    | \$5,104,669.16     | \$6,928,696.74     | \$5,341,524.62      |
| <b>Tier 3</b>              | 5,356            | 3,055             | \$1,779,279.72    | \$1,267,805.30     | \$1,919,518.72     | \$1,383,675.25      |
| <b>Non-specialty Total</b> | 117,016          | 103,968           | \$10,609,782.73   | \$8,366,009.61     | \$11,673,574.43    | \$9,290,746.63      |
| <b>Specialty</b>           |                  |                   |                   |                    |                    |                     |
| <b>Tier 1</b>              | 431              | 364               | \$531,603.30      | \$439,440.44       | \$536,742.61       | \$445,514.60        |
| <b>Tier 2</b>              | 963              | 802               | \$9,071,214.22    | \$6,571,453.48     | \$9,135,969.25     | \$6,615,339.83      |
| <b>Tier 3</b>              | 169              | 210               | \$1,507,951.13    | \$1,716,886.53     | \$1,516,407.97     | \$1,726,548.53      |
| <b>Specialty Total</b>     | 1,563            | 1,376             | \$11,110,768.65   | \$8,727,780.45     | \$11,189,119.83    | \$8,787,402.96      |



# RX UTILIZATION


...

Detailed Review of Rx Claims  
from Plan Sponsor Utilization






# CHANNEL SUMMARY



| Channel    | Total Plan Paid | % of Total |
|------------|-----------------|------------|
| Mail Order | \$1,676,819     | 7.72%      |
| Retail     | \$8,932,964     | 41.13%     |
| Specialty  | \$11,110,769    | 51.15%     |




# GENERIC SUMMARY

Generic Dispensing Rate

**85.44%**

Past GDR:

85.09%



# TOP 10 BRAND DRUGS NON-SPECIALTY



| Product Name | Most Common Indicator | Current           |          |             |                  |             | Previous          |          |             |                  |             |
|--------------|-----------------------|-------------------|----------|-------------|------------------|-------------|-------------------|----------|-------------|------------------|-------------|
|              |                       | Utilizing Members | Rx Count | Member Paid | Copay Assistance | Plan Paid   | Utilizing Members | Rx Count | Member Paid | Copay Assistance | Plan Paid   |
| Trulicity    | Diabetic              | 91                | 682      | \$14,646    | \$70             | \$776,133   | 88                | 687      | \$13,665    | \$0              | \$744,708   |
| Wegovy       | Anti-Obesity Agents   | 68                | 445      | \$20,890    | \$0              | \$595,248   | 14                | 74       | \$1,995     | \$0              | \$102,776   |
| Ozempic      | Diabetic              | 89                | 480      | \$8,357     | \$40             | \$534,471   | 47                | 289      | \$7,685     | \$130            | \$303,965   |
| Eliquis      | Blood Thinners        | 131               | 631      | \$21,001    | \$0              | \$437,496   | 113               | 543      | \$18,018    | \$0              | \$369,998   |
| Jardiance    | Diabetic              | 101               | 650      | \$22,124    | \$0              | \$437,191   | 68                | 425      | \$11,770    | \$0              | \$270,128   |
| Xarelto      | Blood Thinners        | 62                | 341      | \$13,411    | \$0              | \$249,150   | 46                | 261      | \$7,346     | \$0              | \$206,271   |
| Mounjaro     | Diabetic              | 30                | 184      | \$2,900     | \$45             | \$211,781   | 7                 | 15       | \$270       | \$0              | \$17,274    |
| Farxiga      | Diabetic              | 45                | 299      | \$15,470    | \$0              | \$179,644   | 27                | 169      | \$9,549     | \$0              | \$103,368   |
| Trelegy      | Sympathomimetics      | 42                | 237      | \$6,358     | \$0              | \$157,572   | 28                | 173      | \$4,932     | \$0              | \$109,932   |
| Biktarvy     | Antivirals            | 5                 | 41       | \$1,435     | \$0              | \$152,039   | 4                 | 29       | \$915       | \$0              | \$101,540   |
| Total        |                       | 664               | 3,990    | \$126,592   | \$155            | \$3,730,725 | 442               | 2,665    | \$76,145    | \$130            | \$2,329,961 |

# TOP 10 GENERIC DRUGS NON-SPECIALTY



| Product Name                 | Most Common Indicator        | Current           |          |             |                  |           | Previous          |          |             |                  |           |
|------------------------------|------------------------------|-------------------|----------|-------------|------------------|-----------|-------------------|----------|-------------|------------------|-----------|
|                              |                              | Utilizing Members | Rx Count | Member Paid | Copay Assistance | Plan Paid | Utilizing Members | Rx Count | Member Paid | Copay Assistance | Plan Paid |
| Atorvastatin                 | Cardiovascular Agents        | 681               | 3,991    | \$15,518    | \$0              | \$59,565  | 610               | 3,565    | \$15,317    | \$0              | \$64,311  |
| Rosuvastatin                 | Cardiovascular Agents        | 386               | 2,148    | \$8,464     | \$0              | \$59,488  | 304               | 1,667    | \$6,407     | \$0              | \$27,893  |
| Bupropion                    | Antidepressants              | 359               | 2,210    | \$16,095    | \$0              | \$54,417  | 310               | 1,943    | \$13,960    | \$0              | \$37,063  |
| Amphetaminedextr<br>-ampheta | Amphetamines                 | 149               | 988      | \$7,934     | \$0              | \$46,784  | 141               | 1,011    | \$6,671     | \$0              | \$41,359  |
| Mesalamine                   | Inflammatory Bowel<br>Agents | 26                | 155      | \$1,261     | \$0              | \$46,098  | 23                | 172      | \$1,299     | \$0              | \$82,880  |
| Epinephrine                  | Anaphylaxis Agents           | 107               | 130      | \$1,258     | \$0              | \$43,708  | 87                | 100      | \$1,749     | \$0              | \$30,929  |
| Fluticasone                  | Sympathomimetics             | 48                | 201      | \$2,713     | \$0              | \$37,430  | 45                | 163      | \$2,518     | \$0              | \$40,507  |
| Methylphenidate              | Stimulants                   | 101               | 557      | \$5,157     | \$0              | \$36,627  | 82                | 460      | \$4,050     | \$0              | \$31,344  |
| Losartan                     | Cardiovascular Agents        | 370               | 2,251    | \$17,424    | \$0              | \$33,105  | 312               | 1,923    | \$15,977    | \$0              | \$24,251  |
| Albuterol                    | Sympathomimetics             | 598               | 1,248    | \$8,603     | \$0              | \$31,754  | 534               | 1,047    | \$7,501     | \$0              | \$33,920  |
| Total                        |                              | 2,825             | 13,879   | \$84,429    | \$0              | \$448,975 | 2,448             | 12,051   | \$75,448    | \$0              | \$414,457 |

# TOP 10 SPECIALTY DRUGS



| Product Name | Most Common Indicator           | Current  |             |                  |             | Previous |             |                  |             |
|--------------|---------------------------------|----------|-------------|------------------|-------------|----------|-------------|------------------|-------------|
|              |                                 | Rx Count | Member Paid | Copay Assistance | Plan Paid   | Rx Count | Member Paid | Copay Assistance | Plan Paid   |
| Stelara      | Antipsoriatics                  | 74       | \$8,446     | \$1,585          | \$1,934,428 | 45       | \$1,075     | \$1,425          | \$1,110,473 |
| Humira       | Systemic Inflammatory Agents    | 175      | \$5,893     | \$12,880         | \$1,391,594 | 142      | \$3,275     | \$3,870          | \$1,023,786 |
| Trikafta     | Cystic Fibrosis Agents          | 41       | \$1,400     | \$0              | \$1,026,777 | 20       | \$195       | \$0              | \$509,676   |
| Orenitram    | Pulmonary Arterial Hypertension | 26       | \$1,120     | \$0              | \$655,514   | 24       | \$980       | \$0              | \$606,369   |
| Promacta     | Hematopoietic Growth Factors    | 32       | \$237       | \$275            | \$479,574   | 26       | \$62        | \$275            | \$271,430   |
| Skyrizi      | Antipsoriatics                  | 22       | \$660       | \$1,060          | \$448,234   | 2        | \$10        | \$130            | \$37,575    |
| Taltz        | Antipsoriatics                  | 64       | \$930       | \$950            | \$443,311   | 60       | \$595       | \$1,235          | \$397,391   |
| Dupixent     | Topical Agents                  | 118      | \$843       | \$1,727          | \$437,631   | 99       | \$311       | \$1,990          | \$350,237   |
| Xtandi       | Hormonal Agents                 | 29       | \$2,240     | \$0              | \$378,879   | 24       | \$460       | \$0              | \$302,337   |
| Otezla       | Systemic Inflammatory Agents    | 50       | \$349       | \$1,151          | \$237,520   | 62       | \$535       | \$1,290          | \$268,226   |
| Total        |                                 | 631      | \$22,118    | \$19,628         | \$7,433,460 | 504      | \$7,498     | \$10,215         | \$4,877,499 |